More on CGEM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.79 |
|
|||
| Open | $21.88 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $22.79 | ||||
| Day Low | $21.75 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 320,648 | ||||
- TD Cowen Assumes Cullinan Oncology Inc. (CGEM) at Buy
- Zipalertinib trial data to be presented at IASLC lung cancer conference
- Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
- Cullinan Oncology Inc. (CGEM) PT Raised to $27 at UBS
- Form 4 Cullinan Therapeutics, For: Aug 13 Filed by: Michaelson Jennifer
- Zipalertinib combo meets Phase 3 trial goal in lung cancer study
- Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell
- Cullinan Oncology, Inc. (CGEM) Reports In-Line Q2 EPS
- Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Cullinan Therapeutics to advance CLN-049 to Phase 2 AML study
Entities mentioned with CGEM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
